169 related articles for article (PubMed ID: 23591194)
1. Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements.
You B; Harvey R; Henin E; Mitchell H; Golfier F; Savage PM; Tod M; Wilbaux M; Freyer G; Seckl MJ
Br J Cancer; 2013 May; 108(9):1810-6. PubMed ID: 23591194
[TBL] [Abstract][Full Text] [Related]
2. Validation of the Predictive Value of Modeled Human Chorionic Gonadotrophin Residual Production in Low-Risk Gestational Trophoblastic Neoplasia Patients Treated in NRG Oncology/Gynecologic Oncology Group-174 Phase III Trial.
You B; Deng W; Hénin E; Oza A; Osborne R
Int J Gynecol Cancer; 2016 Jan; 26(1):208-15. PubMed ID: 26569059
[TBL] [Abstract][Full Text] [Related]
3. Validation of an online tool for early prediction of the failure-risk in gestational trophoblastic neoplasia patients treated with methotrexate.
Dekeister K; Bolze PA; Tod M; Tod R; Massardier J; Lotz JP; Hajri T; Colomban O; Seckl MJ; Osborne R; Freyer G; Golfier F; You B
Cancer Chemother Pharmacol; 2020 Jul; 86(1):15-24. PubMed ID: 32500221
[TBL] [Abstract][Full Text] [Related]
4. Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias.
You B; Pollet-Villard M; Fronton L; Labrousse C; Schott AM; Hajri T; Girard P; Freyer G; Tod M; Tranchand B; Colomban O; Ribba B; Raudrant D; Massardier J; Chabaud S; Golfier F
Ann Oncol; 2010 Aug; 21(8):1643-1650. PubMed ID: 20154304
[TBL] [Abstract][Full Text] [Related]
5. Early prediction of post-molar gestational trophoblastic neoplasia and resistance to methotrexate, based on a single serum human chorionic gonadotropin measurement.
Hoeijmakers YM; Eysbouts YK; Massuger LFAG; Dandis R; Inthout J; van Trommel NE; Ottevanger PB; Thomas CMG; Sweep FCGJ
Gynecol Oncol; 2021 Dec; 163(3):531-537. PubMed ID: 34602288
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for second-line dactinomycin failure after methotrexate treatment for low-risk gestational trophoblastic neoplasia: a retrospective study.
Hoeijmakers YM; Sweep F; Lok C; Ottevanger PB
BJOG; 2020 Aug; 127(9):1139-1145. PubMed ID: 32141676
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Oral Vitamin A in Reducing β-hCG Levels in Low-Risk Gestational Trophoblastic Neoplasia Patients.
Hidayat YM; Darmadi A E; Rachmayati S; Kusumah WP; Djuwantono T; Pramatirta AY; Suardi D
Asian Pac J Cancer Prev; 2020 Nov; 21(11):3325-3329. PubMed ID: 33247691
[TBL] [Abstract][Full Text] [Related]
8. Doppler-based predictive model for methotrexate resistance in low-risk gestational trophoblastic neoplasia with myometrial invasion: prospective study of 147 patients.
Qin J; Zhang S; Poon L; Pan Z; Luo J; Yu N; Wang L; Wu X; Cheng X; Xie X; Lu Y; Lu W
Ultrasound Obstet Gynecol; 2021 May; 57(5):829-839. PubMed ID: 32385928
[TBL] [Abstract][Full Text] [Related]
9. Uterine artery pulsatility index and serum BMP-9 predict resistance to methotrexate therapy in gestational trophoblastic neoplasia: A cohort study.
Harvey RA; Elias KM; Lim A; Bercow A; Short D; Horowitz NS; Berkowitz RS; Agarwal R; Seckl MJ
Curr Probl Cancer; 2021 Feb; 45(1):100622. PubMed ID: 32800689
[TBL] [Abstract][Full Text] [Related]
10. Human Chorionic Gonadotropin (hCG) Regression Curve for Predicting Response to EMA/CO (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide and Vincristine) Regimen in Gestational Trophoblastic Neoplasia.
Rattanaburi A; Boonyapipat S; Supasinth Y
Asian Pac J Cancer Prev; 2015; 16(12):5037-41. PubMed ID: 26163637
[TBL] [Abstract][Full Text] [Related]
11. Increasing the human chorionic gonadotrophin cut-off to ≤1000 IU/l for starting actinomycin D in post-molar gestational trophoblastic neoplasia developing resistance to methotrexate spares more women multi-agent chemotherapy.
Cortés-Charry R; Hennah L; Froeling FEM; Short D; Aguiar X; Tin T; Harvey R; Unsworth N; Kaur B; Savage P; Sarwar N; Seckl MJ
ESMO Open; 2021 Jun; 6(3):100110. PubMed ID: 33845362
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Combination Therapy with Actinomycin D and Methotrexate in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia.
Kang HL; Zhao Q; Yang SL; Duan W
Chemotherapy; 2019; 64(1):42-47. PubMed ID: 31163446
[TBL] [Abstract][Full Text] [Related]
13. Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia.
Lybol C; Sweep FC; Harvey R; Mitchell H; Short D; Thomas CM; Ottevanger PB; Savage PM; Massuger LF; Seckl MJ
Gynecol Oncol; 2012 Jun; 125(3):576-9. PubMed ID: 22410329
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors of relapse in low-risk gestational trophoblastic neoplasia patients successfully treated with methotrexate alone.
Couder F; Massardier J; You B; Abbas F; Hajri T; Lotz JP; Schott AM; Golfier F
Am J Obstet Gynecol; 2016 Jul; 215(1):80.e1-7. PubMed ID: 26829503
[TBL] [Abstract][Full Text] [Related]
15. Human chorionic gonadotropin (hCG) regression normograms for patients with high-risk gestational trophoblastic neoplasia treated with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy.
Lybol C; Westerdijk K; Sweep FCGJ; Ottevanger PB; Massuger LFAG; Thomas CMG
Ann Oncol; 2012 Nov; 23(11):2903-2906. PubMed ID: 22730100
[TBL] [Abstract][Full Text] [Related]
16. The value of an initial drop in human Chorionic gonadotropin levels in predicting a response to methotrexate in women with low-risk gestational trophoblastic neoplasia.
Banach P; Zaborowski MP; Izycka N; Romala A; Nowak-Markwitz E
Ginekol Pol; 2019; 90(3):141-147. PubMed ID: 30950003
[TBL] [Abstract][Full Text] [Related]
17. [Effects of primary chemotherapy with single methotrexate on low-risk gestational trophoblastic neoplasia and influencing factors thereof].
Chen YX; Shen YM; Qian JH; Xie X
Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2109-12. PubMed ID: 16313819
[TBL] [Abstract][Full Text] [Related]
18. Transvaginal ultrasound predicts delayed response to chemotherapy and drug resistance in stage I low-risk trophoblastic neoplasia.
Cavoretto P; Gentile C; Mangili G; Garavaglia E; Valsecchi L; Spagnolo D; Montoli S; Candiani M
Ultrasound Obstet Gynecol; 2012 Jul; 40(1):99-105. PubMed ID: 22262502
[TBL] [Abstract][Full Text] [Related]
19. Comparison of 5-day MTX and 5-day ETP treatment results and early predictors of drug resistance to 5-day MTX in patients with post-molar low-risk gestational trophoblastic neoplasia.
Kizaki S; Hashimoto K; Matsui H; Usui H; Shozu M
Gynecol Oncol; 2015 Dec; 139(3):429-32. PubMed ID: 26456138
[TBL] [Abstract][Full Text] [Related]
20. Early identification of resistance to first-line single-agent methotrexate in patients with persistent trophoblastic disease.
van Trommel NE; Massuger LF; Schijf CP; ten Kate-Booij MJ; Sweep FC; Thomas CM
J Clin Oncol; 2006 Jan; 24(1):52-8. PubMed ID: 16382113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
